Coherus BioSciences CHRS 20.03% announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.
Coherus BioSciences shares were trading lower by 13% at $19.77 on Monday morning. The stock has a 52-week high of $23.43 and a 52-week low of $8.32.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.